15% OFF 
KPV – 500mcg × 100 Capsules (Research Use Only)
KPV (Lys-Pro-Val), the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, studied in NF-κB signalling and rodent models of intestinal inflammation. Supplied for laboratory research and identification purposes only.
Availability: In stock
3–4 vials — 5% off · 5–9 vials — 10% off · 10+ vials — 15% off
Applied automatically in the cart. Combines with a discount code up to 20% off in total, and stacks on top of the subscription discount.
Research Disclaimer: All products currently listed on this site are for research purposes only.
Overview
KPV is a synthetic tripeptide (Lys-Pro-Val) corresponding to the C-terminal alpha-melanocyte-stimulating hormone (α-MSH) fragment responsible for its anti-inflammatory activity. First characterized in published research exploring which structural elements of α-MSH confer its anti-inflammatory and immunomodulatory properties, KPV has been studied in models of gastrointestinal inflammation, skin barrier biology, and systemic inflammatory signaling. Its small molecular size and reported ability to interact with cellular inflammatory machinery independent of melanocortin receptor binding has generated research interest in it as a mechanistic tool for dissecting α-MSH biology.
What It Is
KPV (Lys-Pro-Val) is the C-terminal tripeptide (positions 11-13) of alpha-melanocyte-stimulating hormone (α-MSH), with MW approximately 340 Da, CAS number 49557-75-7. Published research has documented KPV’s inhibitory effects on NF-κB activation, IL-1β production, and inflammatory cytokine cascades in cell culture and animal models. Unlike full-length α-MSH, KPV’s immunomodulatory activity has been characterized as at least partly independent of melanocortin receptor engagement, making it a useful mechanistic tool in inflammatory pathway research.
Key Research Applications
- NF-κB pathway inhibition and pro-inflammatory cytokine suppression research
- α-MSH C-terminal fragment anti-inflammatory mechanism dissection studies
- Gastrointestinal inflammation modeling — colitis and intestinal permeability research
- Skin keratinocyte and dermal fibroblast inflammatory response studies
- IL-1β, TNF-α, and IL-6 cytokine pathway modulation research
- Melanocortin receptor-independent anti-inflammatory mechanism studies
- Gut microbiome and mucosal immune response interaction research
- Comparative α-MSH fragment pharmacology (KPV vs. full-length α-MSH vs. SHU9119)
Technical Specifications
| Amino Acids | 3 (Lys-Pro-Val) |
| Molecular Weight | ~340 Da |
| CAS Number | 49557-75-7 |
| Parent Peptide | α-MSH C-terminal fragment (positions 11-13) |
| Purity | ≥98% (supplier specification) |
| Form | Oral capsule (500mcg) |
| Quantity | 100 capsules per bottle |
| Storage | Cool, dry place away from heat, moisture and direct light |
FOR RESEARCH USE ONLY. Not intended for human or veterinary consumption, medical diagnosis, treatment, or prevention of any disease or condition. This product has not been evaluated by the FDA or any regulatory agency. Must be handled by qualified research personnel in a compliant laboratory setting. These statements have not been evaluated by the Food and Drug Administration.
Not sure which compounds fit your research? Browse the Research Hub →
Related research (educational)
- Overlapping Pathways in Circadian, Repair and Mitochondrial Biology
- Recovery & Repair Research Compounds: A Complete Guide
- BPC-157 and TB-500: Preclinical Literature Compared
Regulatory Status Note
On July 23–24, 2026, FDA’s Pharmacy Compounding Advisory Committee reviewed whether BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, and emideltide (DSIP) should be added to the 503A Bulks List for pharmacy compounding. The committee voted to recommend six of the seven; emideltide (DSIP) was not recommended. FDA’s own briefing documents had recommended against all seven.
A committee vote is a recommendation only. It does not constitute FDA approval, does not establish safety or effectiveness, and does not change the status of this product, which is sold strictly for research use. FDA must complete formal rulemaking before any substance is added to the list. Source: FDA Advisory Committee Calendar. Last reviewed: August 17, 2026.
Update — July 24, 2026: On July 23, the committee voted. BPC-157, KPV, and TB-500 each passed 8-6 with one abstention; MOTS-c passed 7-5 with two abstentions. The recommendation is non-binding — FDA is not required to follow it, must still issue a formal decision, and the process may require additional rulemaking before any compounding pharmacy could act on it. No peptide has been FDA-approved, and this update does not constitute or imply a therapeutic claim. Source: STAT News
- Processing: Orders ship within 1–2 business days
- Domestic delivery: 3–5 business days via USPS Priority / UPS Ground
- Free shipping on orders over $100
- Temperature handling: Cold-chain packaging available on request for lyophilized peptides
- Tracking: Emailed automatically at time of dispatch
- Store in a cool, dry place away from heat, moisture and direct light
- Keep the container tightly closed
Frequently Asked Questions
KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (α-MSH). It is studied in NF-κB signalling and in rodent models of intestinal inflammation. Human evidence is not established. Portal to Wellness does not publish protocols, combinations or quantities, and nothing on this page is a recommendation for use.
Pairs Well With
Related research products
Reviews
There are no reviews yet.